Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 11 de 11
Filter
1.
Genet Mol Res ; 15(3)2016 Sep 02.
Article in English | MEDLINE | ID: mdl-27706681

ABSTRACT

Drug resistance in cells is a major impedance to successful treatment of lung cancer. Taxus chinensis var. inhibits the growth of tumor cells and promotes the synthesis of interleukins 1 and 2 and tumor necrosis factor, enhancing immune function. In this study, T. chinensis var.-induced cell death was analyzed in lung cancer cells (H460) enriched for stem cell growth in a defined serum-free medium. Taxus-treated stem cells were also analyzed for Rhodamine 123 (Rh-123) expression by flow cytometry, and used as a standard functional indicator of MDR. The molecular basis of T. chinensis var.-mediated drug resistance was established by real-time PCR analysis of ABCC1, ABCB1, and lung resistance-related protein (LRP) mRNA, and western blot analysis of MRP1, MDR1, and LRP. Our results revealed that stem cells treated with higher doses of T. chinensis var. showed significantly lower growth inhibition rates than did H460 cells (P < 0.05). The growth of stem and H460 cells treated with a combination of T. chinensis var. and cisplatin was also significantly inhibited (P < 0.05). Rh-123 was significantly accumulated in the intracellular region and showed delayed efflux in stem cells treated with T. chinensis var. (P < 0.05), compared to those treated with verapamil. T. chinensis var.-treated stem cells showed significant downregulation of the ABCC1, ABCB1, and LRP mRNA and MRP1, MDR1, and LRP (P < 0.05) compared to H460 cells. Thus, T. chinensis var.-mediated downregulation of MRP1, MDR1, and LRP might contribute to the reversal of drug resistance in non-small cell lung cancer stem cells.


Subject(s)
Antineoplastic Agents/pharmacology , Drug Resistance, Neoplasm/drug effects , Gene Expression Regulation, Neoplastic , Neoplastic Stem Cells/drug effects , Plant Extracts/pharmacology , Taxus/chemistry , ATP Binding Cassette Transporter, Subfamily B/antagonists & inhibitors , ATP Binding Cassette Transporter, Subfamily B/genetics , ATP Binding Cassette Transporter, Subfamily B/metabolism , Antineoplastic Agents/chemistry , Carcinoma, Non-Small-Cell Lung/drug therapy , Carcinoma, Non-Small-Cell Lung/genetics , Carcinoma, Non-Small-Cell Lung/metabolism , Carcinoma, Non-Small-Cell Lung/pathology , Cell Line, Tumor , Cisplatin/pharmacology , Drug Combinations , Drug Resistance, Neoplasm/genetics , Drugs, Chinese Herbal , Humans , Lung Neoplasms/drug therapy , Lung Neoplasms/genetics , Lung Neoplasms/metabolism , Lung Neoplasms/pathology , Multidrug Resistance-Associated Proteins/antagonists & inhibitors , Multidrug Resistance-Associated Proteins/genetics , Multidrug Resistance-Associated Proteins/metabolism , Neoplastic Stem Cells/metabolism , Neoplastic Stem Cells/pathology , Plant Extracts/chemistry , Rhodamine 123/metabolism , Signal Transduction , Vault Ribonucleoprotein Particles/antagonists & inhibitors , Vault Ribonucleoprotein Particles/genetics , Vault Ribonucleoprotein Particles/metabolism
2.
Oncol Rep ; 25(3): 781-8, 2011 Mar.
Article in English | MEDLINE | ID: mdl-21165580

ABSTRACT

Tanshinone IIA is known to induce apoptosis in several types of cancer cells. However, little is known about its activity in chemoresistant cells. The aim of this study was to investigate the anticancer properties of tanshinone IIA in cisplatin-resistant human ovarian cancer COC1/DDP cells in vitro. We used a variety of methods to measure cell viability, the resistance index (RI) of cisplatin, cellular apoptosis, p38 mitogen-activated protein kinase (MAPK) expression and phosphorylation, and the mRNA expression of several genes implicated in drug resistance including survivin, Caspase-3, excision repair cross-complementing gene 1 (ERCC1), multidrug resistance (MDR), lung resistance protein (LRP) and glutathione-S-transferase-π (GST-π). We found that tanshinone IIA time- and dose-dependently inhibited the proliferation of COC1/DDP cells and caused significant apoptosis. Western blotting revealed that tanshinone IIA also increased phospho-p38 MAPK in a time- and dose-dependent manner. After treatment by tanshinone IIA for 48 h, the RI of cisplatin and the mRNA expression of survivin, ERCC1 and LRP were all significantly decreased. Furthermore, blockade of p38 signal transduction decreased apoptotic cell rates and dramatically elevated the mRNA expression of the survivin, ERCC1 and LRP genes. We therefore conclude that tanshinone IIA induces apoptosis and reduces cisplatin resistance in COC1/DDP cells and thus causes significant growth inhibitory effects. This mechanism appears to involve p38-mediated downregulation of survivin, ERCC1 and LRP mRNA expression.


Subject(s)
Abietanes/pharmacology , Apoptosis/drug effects , Carcinoma/pathology , DNA-Binding Proteins/genetics , Endonucleases/genetics , Ovarian Neoplasms/pathology , Vault Ribonucleoprotein Particles/genetics , p38 Mitogen-Activated Protein Kinases/physiology , Abietanes/therapeutic use , Antineoplastic Agents/pharmacology , Antineoplastic Agents/therapeutic use , Carcinoma/drug therapy , Carcinoma/genetics , Cell Line, Tumor , Cisplatin/therapeutic use , DNA-Binding Proteins/metabolism , Down-Regulation/drug effects , Drug Evaluation, Preclinical , Drug Resistance, Neoplasm/drug effects , Drug Resistance, Neoplasm/genetics , Endonucleases/metabolism , Female , Gene Expression Regulation, Neoplastic/drug effects , Humans , Ovarian Neoplasms/drug therapy , Ovarian Neoplasms/genetics , Signal Transduction/drug effects , Vault Ribonucleoprotein Particles/metabolism , p38 Mitogen-Activated Protein Kinases/metabolism
3.
Zhongguo Zhong Yao Za Zhi ; 32(18): 1906-8, 2007 Sep.
Article in Chinese | MEDLINE | ID: mdl-18051904

ABSTRACT

OBJECTIVE: To observe the effect on P170, LRP, TOPO II of S180 tumour MDR mice for matter by 70% ethanol with Huanglian Jiedu Tang, and then discuss the molecular biology base for clinic. METHOD: 18-22 gramme mice were divided into four groups for normal S180 tumour cell group, matter by 70% ethanol with Huanglian Jiede Tang 100 mg x kg(-1) and 50 mg x kg(-1) in random. Each mouse was given S180 cell 0.2 mL by celiac, and after 24 hours give cisplatin for Injective 3 mg x kg(-1), ip, once a week. And give cyclophosphamide and 5-FU 3 mg x kg(-1), ig, once every day. After 15 days, collect lively mice ascites and give it for onefold normal mice. And then repeat before process. At the same time, every group was given corresponding medicine for 0.2 mL x 10 g(-1). The normal group and the model group were given the same cubage water, all together fore weeks. At last observd the P170, LRP, TOPO II by flow cytometry. RESULT: Matter by 70% ethanol with Huanglian Jiedu Tang could obviously reduce the express of P170 and LRP, and the activiation of TOPO II. CONCLUSION: Matter by 70% ethanol with Huanglian Jiedu Tang can intervene the ocurrence of the multi-drug resistance of tumour cells by regulating the biology gene.


Subject(s)
Drug Resistance, Multiple/drug effects , Drug Resistance, Neoplasm/drug effects , Drugs, Chinese Herbal/pharmacology , Sarcoma 180/prevention & control , ATP Binding Cassette Transporter, Subfamily B, Member 1/metabolism , Animals , Cell Line, Tumor , Coptis/chemistry , DNA Topoisomerases, Type II/metabolism , Drug Combinations , Drugs, Chinese Herbal/chemistry , Drugs, Chinese Herbal/isolation & purification , Ethanol/chemistry , Flow Cytometry , Mice , Phytotherapy , Plants, Medicinal/chemistry , Sarcoma 180/metabolism , Sarcoma 180/pathology , Vault Ribonucleoprotein Particles/metabolism
4.
Zhongguo Zhong Yao Za Zhi ; 30(16): 1280-2, 2005 Aug.
Article in Chinese | MEDLINE | ID: mdl-16245910

ABSTRACT

OBJECTIVE: To observe the effect of tetrandrine on the P170 production expressed by multi-drug resistance gene, lung resistant protein (LRP), and topoisomeras II and elucidate the underlying molecular mechanism. METHOD: Cellular model of multi-drug resistance was established in S180 tumor cell by means of the scheme of PFC chemotherapy at the dosage lower than that with curative effect. P170, LRP and TOPO II were measured by flow cytometry after the mouse model was treated with tetrandrine for 4 weeks. RESULT: tetrandrine obviously reduced the enhancement of express of P170, LRP and the activity of TOPO II in the tumor cells with multi-drug resistance induced by chemotherapy. CONCLUSION: Tetrandrine significantly inhibits the multi-drug resistance of tumor cells induced by chemotherapy via diminishing both the expression of multi-drug resistance gene and the activity of topoisomeras II.


Subject(s)
ATP Binding Cassette Transporter, Subfamily B, Member 1/metabolism , Alkaloids/pharmacology , Benzylisoquinolines/pharmacology , DNA Topoisomerases, Type II/metabolism , Sarcoma 180/metabolism , Vault Ribonucleoprotein Particles/metabolism , Animals , Drug Resistance, Multiple , Drug Resistance, Neoplasm , Drugs, Chinese Herbal/pharmacology , Gene Expression Regulation, Neoplastic , Genes, MDR , Mice , Random Allocation , Sarcoma 180/enzymology , Sarcoma 180/pathology
5.
Zhongguo Zhong Yao Za Zhi ; 30(23): 1844-8, 2005 Dec.
Article in Chinese | MEDLINE | ID: mdl-16499024

ABSTRACT

OBJECTIVE: To observe the base of the interference in correlated biotic active matter obtained multi-drug resistance induced by chemotherapy for different alkaloid, and to supervise the use in clinic to restrain the multi-drug resistant of chemotherapy, and thereby to improve the curative effect. METHOD: After bestowing subter-dosage unite chemotherapeutant to ascites S180 mouse to set up the mouse models of multi-drug resistance of S180 tumour cell, and giving the mouse matrine, terandrine, oxymatrine and berberine hydrooh loride for 4 weeks, the P170, LRP, TOPOII, Fas and apoposis were determined by flow cytometry. RESULT: Matrine and terandrine could obviously reduce the express of P170, LRP and the activation of TOPOII, and increase the ratio of the express of Fas and the apoposis of drug resistant tumour cell. And at the same time it could obviously reduce the express of intercellular adhesion molecule(CD54). CONCLUSION: Matrine and terandrine can interfere in MDR which results from chemotherapeutics by the adjustment of correlated biotic active matter, besides, the different degree of alkaloid effect with different configuration.


Subject(s)
ATP Binding Cassette Transporter, Subfamily B, Member 1/metabolism , Alkaloids/pharmacology , Benzylisoquinolines/pharmacology , Drug Resistance, Multiple , Drug Resistance, Neoplasm , Quinolizines/pharmacology , Sarcoma 180/pathology , Alkaloids/isolation & purification , Animals , Apoptosis/drug effects , Benzylisoquinolines/isolation & purification , Berberine Alkaloids/isolation & purification , Berberine Alkaloids/pharmacology , DNA Topoisomerases, Type II/metabolism , Female , Male , Mice , Plants, Medicinal/chemistry , Quinolizines/isolation & purification , Random Allocation , Sarcoma 180/metabolism , Tumor Cells, Cultured , Vault Ribonucleoprotein Particles/metabolism , fas Receptor/metabolism , Matrines
6.
Cancer ; 101(8): 1908-18, 2004 Oct 15.
Article in English | MEDLINE | ID: mdl-15386340

ABSTRACT

BACKGROUND: Nonsmall cell lung carcinomas (NSCLCs) are associated with very dismal prognoses, and adjuvant chemotherapy, including irinotecan, taxanes, platin, and vinca alkaloid derivatives, offer patients only slight clinical benefits. Part of the chemoresistance of NSCLC results from the expression in NSCLC cells of a very large set of endogenous proteins, which antagonize chemotherapy-mediated attacks on these tumor cells. METHODS: The authors set up an orthotopic model of a human NSCLC by grafting A549 cells into the lungs of nude mice. They tried treating these A549 NSCLC orthotopic xenograft-bearing nude mice on the basis of various chemotherapeutic protocols, including chronic administrations of taxol, oxaliplatin, and irinotecan. A cyclooxygenase-2 (COX-2) inhibitor (NS-398) also was assayed in combination with taxol. The immunohistochemical expression levels of COX-2, prostaglandin E synthetase (PGES), ornithine decarboxylase (ODC), the lung-related resistance protein (LRP), and glutathione-S-transferase-alpha (GST-alpha), GST-mu, and GST-pi were quantitatively determined by means of computer-assisted microscopy in control and drug-treated NSCLC orthotopic xenografts. RESULTS: The orthotopic A549 xenograft model developed in 100% of the grafted mice, leading to brain metastases in approximately 61% mice and to liver metastases in approximately 40% of mice. The model was resistant to taxol and oxaliplatin and was only weakly sensitive to irinotecan. High levels of chemoresistant markers (i.e., COX-2, PGES, ODC, LRP, GST-alpha, GST-mu, and GST-pi) were observed in the nontreated A549 xenografts, although with dramatic variations in individual expression. Taxol and oxaliplatin significantly increased the levels of expression of COX-2, PGES, GST-mu, and GST-pi in a number of different experimental protocols. CONCLUSIONS: The A549 orthotopic xenograft model could be used to evaluate investigational chemotherapeutic agents to identify drugs rapidly that are more active than the drugs currently in use in hospitals.


Subject(s)
Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Biomarkers, Tumor/metabolism , Brain Neoplasms/drug therapy , Camptothecin/analogs & derivatives , Carcinoma, Non-Small-Cell Lung/drug therapy , Disease Models, Animal , Drug Resistance, Neoplasm , Liver Neoplasms/drug therapy , Lung Neoplasms/drug therapy , Animals , Brain Neoplasms/metabolism , Brain Neoplasms/secondary , Camptothecin/administration & dosage , Carcinoma, Non-Small-Cell Lung/metabolism , Carcinoma, Non-Small-Cell Lung/pathology , Cyclooxygenase 2 , Female , Glutathione S-Transferase pi , Glutathione Transferase/metabolism , Humans , Intramolecular Oxidoreductases/metabolism , Irinotecan , Isoenzymes/metabolism , Liver Neoplasms/metabolism , Liver Neoplasms/secondary , Lung Neoplasms/metabolism , Lung Neoplasms/pathology , Membrane Proteins , Mice , Mice, Nude , Neoplasm Proteins/metabolism , Organoplatinum Compounds/administration & dosage , Ornithine Decarboxylase/metabolism , Oxaliplatin , Paclitaxel/administration & dosage , Prostaglandin-E Synthases , Prostaglandin-Endoperoxide Synthases/metabolism , Survival Rate , Transplantation, Heterologous , Vault Ribonucleoprotein Particles/metabolism
7.
Oncol Rep ; 11(3): 641-5, 2004 Mar.
Article in English | MEDLINE | ID: mdl-14767515

ABSTRACT

Primary malignant fibrous histiocytoma (MFH) of the heart is a rare and highly malignant soft tissue tumor, which is largely resistant to conventional chemotherapy and radiotherapy. Therefore, we analyzed growth inhibitory effects of different chemotherapeutic agents and mechanisms of drug resistance in the recently established cell line MFH-H derived from a human primary cardiac MFH. The growth inhibitory effects of etoposide, vincristine, and paclitaxel were tested using the MTT assay. The expression and function of multidrug resistance-related proteins, i.e. the P-glycoprotein, the multidrug resistance-associated protein (MRP) and the lung resistance-related protein (LRP) were determined by FACScan and functional assays of cellular drug efflux. The concentration required for a 50% inhibition of growth (IC50) was 0.001 microM for etoposide and 0.035 microM for vincristine. Paclitaxel dissolved in Cremophor EL/ethanol inhibited the cell growth of MFH-H cells more intensively (IC50: 0.27 microM) than paclitaxel dissolved in DMSO (IC50: 11.09 microM) suggesting that Cremophor EL is contributing to the inhibitory effects of paclitaxel. The response of MFH-H to etoposide, vincristine and paclitaxel/Taxol could not be predicted by the expression and function of P-glycoprotein, MRP and LRP. This study demonstrates that etoposide and to a lesser extent vincristine can effectively inhibit the growth of MFH-H cells, irrespective of the multidrug resistance phenotype. MFH-H cells are relatively insensitive to paclitaxel dissolved in DMSO, in contrast to paclitaxel dissolved in Cremophor EL/ethanol indicating that the diluent Cremophor contributes to the antiproliferative effects of the taxane paclitaxel.


Subject(s)
Alkaloids/therapeutic use , Drug Resistance, Multiple , Heart Neoplasms/drug therapy , Histiocytoma, Benign Fibrous/drug therapy , Plant Extracts/therapeutic use , Soft Tissue Neoplasms/drug therapy , ATP Binding Cassette Transporter, Subfamily B, Member 1/metabolism , Antineoplastic Agents, Phytogenic/pharmacology , Cell Line, Tumor , Cell Separation , Cell Survival , Cells, Cultured , Coloring Agents/pharmacology , Dose-Response Relationship, Drug , Drug Resistance, Neoplasm , Etoposide/pharmacology , Flow Cytometry , Humans , Inhibitory Concentration 50 , Paclitaxel/pharmacology , Phenotype , Tetrazolium Salts/pharmacology , Thiazoles/pharmacology , Vault Ribonucleoprotein Particles/metabolism , Vincristine/pharmacology
8.
Zhong Xi Yi Jie He Xue Bao ; 1(3): 221-5, 2003 Sep.
Article in Chinese | MEDLINE | ID: mdl-15339569

ABSTRACT

Multidrug resistance (MDR) is an important biological behavior of tumor cells in chemotherapy. And it is also one of the major causes of clinical chemotherapy failure. According to the literature at home and abroad, and combining with the results of authors' investigations, this paper mainly discusses the mechanism of tumor cells' MDR and its reversion by Chinese herbs.


Subject(s)
Drug Resistance, Multiple/drug effects , Drug Resistance, Neoplasm/drug effects , Drugs, Chinese Herbal/pharmacology , Neoplasms/drug therapy , Glutathione/metabolism , Glycoproteins/metabolism , Humans , Neoplasm Proteins/metabolism , Neoplasms/metabolism , Neoplasms/pathology , Protein Kinase C/metabolism , Vault Ribonucleoprotein Particles/metabolism
9.
J Clin Oncol ; 20(15): 3282-92, 2002 Aug 01.
Article in English | MEDLINE | ID: mdl-12149303

ABSTRACT

PURPOSE: Isolated, hyperthermic limb perfusion (ILP) with recombinant human tumor necrosis factor alpha and melphalan is a highly effective treatment for advanced soft tissue sarcoma (STS) and locoregional metastatic malignant melanoma. Multidrug resistance (MDR)-associated genes are known to be inducible by heat and drugs; expression levels of the major vault protein (MVP), MDR1, and MDR-associated protein 1 (MRP1) were determined sequentially before, during, and after ILP of patients. PATIENTS AND METHODS: Twenty-one STS or malignant melanoma patients were treated by ILP. Tumor tissue temperatures were recorded continuously and ranged from 33.4 degrees C initially to peak values of 40.4 degrees C during ILP. Serial true-cut biopsy specimens from tumor tissues were routinely microdissected. Expression analyses for MDR genes were performed by real-time reverse transcriptase polymerase chain reaction and immunohistochemistry. RESULTS: In 83% of the patients, MVP expression was induced during hyperthermic ILP. MVP-mRNA inductions often paralleled the increase in temperature during ILP. Increased MVP protein expressions either were observed simultaneously with the MVP-mRNA induction or were delayed until after the induction at the transcriptional level. Inductions of MDR1 and MRP1 were observed in only 13% and 27% of the specimens analyzed. Temperatures and drugs applied preferentially led to an induction of MVP and were not sufficient to induce MDR1 and MRP1 in the majority of tumors. CONCLUSION: This study is the first to analyze the expression of MDR-associated genes sequentially during ILP of patients and demonstrates that treatment might lead to increased levels of MVP, whereas enhanced levels of MDR1 and MRP1 remain rare events.


Subject(s)
Chemotherapy, Cancer, Regional Perfusion/methods , Fungal Proteins/genetics , Genes, MDR/genetics , Hyperthermia, Induced , Melanoma/drug therapy , Multidrug Resistance-Associated Proteins/genetics , Repressor Proteins/genetics , Saccharomyces cerevisiae Proteins , Sarcoma/drug therapy , Soft Tissue Neoplasms/drug therapy , Adult , Aged , Antineoplastic Agents/therapeutic use , Antineoplastic Agents, Alkylating/therapeutic use , Child , Female , Humans , Immunohistochemistry , Male , Melanoma/metabolism , Melanoma/pathology , Melphalan/therapeutic use , Middle Aged , Reverse Transcriptase Polymerase Chain Reaction , Sarcoma/metabolism , Sarcoma/pathology , Soft Tissue Neoplasms/metabolism , Soft Tissue Neoplasms/pathology , Statistics, Nonparametric , Treatment Outcome , Tumor Necrosis Factor-alpha/therapeutic use , Vault Ribonucleoprotein Particles/metabolism
10.
Cancer ; 91(10): 1940-8, 2001 May 15.
Article in English | MEDLINE | ID: mdl-11346877

ABSTRACT

BACKGROUND: Multidrug resistance (MDR) is associated with expression of P-glycoprotein (P-gp), multidrug resistance-associated protein 1 (MRP1), and lung resistance-related protein (LRP). Tumor necrosis factor (TNF-alpha) is able to modify the expression of these three proteins in different cell types. The effect of TNF-alpha in the clinical situation on patients with soft tissue sarcomas (STS) is indeterminate. METHODS: Thirty-seven patients with a locally advanced extremity STS underwent hyperthermic isolated limb perfusion (HILP) with TNF-alpha and melphalan; 15 patients received additional interferon gamma. Clinical and histologic responses were documented and used to define the overall response. Samples before and after HILP were analyzed immunohistochemically for P-gp, MRP1, and LRP. Samples were scored as negative or positive (< or = 5% or > 5% positive tumor cells). RESULTS: Six patients had an overall complete response, 25 patients had a partial response, and 4 patients with STS revealed no change; in 2 patients, the response remained unclear. The percentage STS samples that were positive for all three proteins dropped from 92% before HILP to 85% after HILP. P-gp positive samples were encountered more often than MRP1 positive samples (P < 0.05). The percentage of samples that were negative for all three MDR proteins increased after HILP from 6% to 16%. MDR status had no significant correlation with tumor response. CONCLUSIONS: HILP with TNF-alpha and melphalan results in excellent overall tumor response in patients with locally advanced STS. STS more often are positive for P-gp than for MRP1. MDR status in patients with STS is not predictive for tumor response after HILP. Data from the current study suggest that the combination of TNF-alpha and melphalan does not induce MDR positive STS: a result with clinical importance when consecutive, adjuvant, doxorubicin-containing chemotherapy is considered.


Subject(s)
ATP Binding Cassette Transporter, Subfamily B, Member 1/metabolism , ATP-Binding Cassette Transporters/metabolism , Antineoplastic Agents, Alkylating/therapeutic use , Hyperthermia, Induced , Melphalan/therapeutic use , Neoplasm Proteins/metabolism , Sarcoma/drug therapy , Soft Tissue Neoplasms/drug therapy , Tumor Necrosis Factor-alpha/therapeutic use , Vault Ribonucleoprotein Particles/metabolism , Adolescent , Adult , Aged , Aged, 80 and over , Antineoplastic Combined Chemotherapy Protocols , Chemotherapy, Cancer, Regional Perfusion/methods , Drug Resistance, Multiple , Female , Humans , Immunoenzyme Techniques , Interferon-gamma/therapeutic use , Male , Middle Aged , Multidrug Resistance-Associated Proteins , Prognosis , Sarcoma/metabolism , Sarcoma/pathology , Soft Tissue Neoplasms/metabolism , Soft Tissue Neoplasms/pathology , Survival Rate
11.
Mol Pharmacol ; 58(6): 1563-9, 2000 Dec.
Article in English | MEDLINE | ID: mdl-11093797

ABSTRACT

A newly synthesized taxoid originally from the Japanese yew Taxus cuspidata, 5-O-benzoylated taxinine K (BTK) was examined for its ability to reverse P-glycoprotein (P-gp) and multidrug resistance protein (MRP)-mediated multidrug resistance. BTK reversed the resistance to paclitaxel, doxorubicin (ADM), and vincristine (VCR) of KB-8-5 and KB-C2 cells that overexpress P-gp by directly interacting with P-gp. BTK also moderately reversed the resistance to ADM of KB/MRP cells that overexpress MRP. However, BTK neither inhibited the transporting activity of MRP nor reduced intracellular glutathione levels in KB/MRP cells. BTK shifted the distribution of ADM in KB/MRP cells from punctate cytoplasmic compartments to the nucleoplasm and cytoplasm by inhibiting acidification of cytoplasmic organelles. These two functions of BTK make it able to reverse both P-gp- and MRP-mediated MDR. BTK in combination with ADM should be useful for treating patients with tumors that overexpress both P-gp and MRP.


Subject(s)
ATP Binding Cassette Transporter, Subfamily B/metabolism , ATP-Binding Cassette Transporters/metabolism , Antineoplastic Agents/pharmacology , Bridged-Ring Compounds/pharmacology , Taxoids , ATP Binding Cassette Transporter, Subfamily B/drug effects , ATP-Binding Cassette Transporters/drug effects , Azides/metabolism , Biological Transport/drug effects , Dihydropyridines/metabolism , Doxorubicin/pharmacology , Drug Resistance, Neoplasm , Drug Screening Assays, Antitumor , Glutathione/metabolism , Humans , KB Cells , Leukotriene C4/metabolism , Multidrug Resistance-Associated Proteins , Neoplasm Proteins/metabolism , Organelles/drug effects , Organelles/physiology , Paclitaxel/pharmacology , Photoaffinity Labels , Plants, Medicinal , Taxus/chemistry , Tritium , Vault Ribonucleoprotein Particles/metabolism
SELECTION OF CITATIONS
SEARCH DETAIL